CR20200643A - Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2 - Google Patents

Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2

Info

Publication number
CR20200643A
CR20200643A CR20200643A CR20200643A CR20200643A CR 20200643 A CR20200643 A CR 20200643A CR 20200643 A CR20200643 A CR 20200643A CR 20200643 A CR20200643 A CR 20200643A CR 20200643 A CR20200643 A CR 20200643A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
cannabinoid receptor
pyrazine compounds
novel pyridine
sup
Prior art date
Application number
CR20200643A
Other languages
English (en)
Inventor
Uwe Grether
Luca Gobbi
Julian Kretz
Simon M Ametamey
Original Assignee
Eth Zuerich
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich, Hoffmann La Roche filed Critical Eth Zuerich
Publication of CR20200643A publication Critical patent/CR20200643A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a un compuesto de fórmula (I) <img src="data:image/png;base64,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 (***)
CR20200643A 2018-06-27 2019-06-25 Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2 CR20200643A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180137 2018-06-27
PCT/EP2019/066811 WO2020002320A1 (en) 2018-06-27 2019-06-25 Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2

Publications (1)

Publication Number Publication Date
CR20200643A true CR20200643A (es) 2021-05-11

Family

ID=62814868

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200643A CR20200643A (es) 2018-06-27 2019-06-25 Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2

Country Status (18)

Country Link
US (1) US20210115011A1 (es)
EP (1) EP3814329B1 (es)
JP (1) JP7445610B2 (es)
KR (1) KR20210028202A (es)
CN (1) CN112262132A (es)
AU (1) AU2019294256A1 (es)
BR (1) BR112020025013A2 (es)
CA (1) CA3096777A1 (es)
CL (1) CL2020003331A1 (es)
CO (1) CO2020011855A2 (es)
CR (1) CR20200643A (es)
IL (1) IL279725B2 (es)
MA (1) MA53002A (es)
MX (1) MX2020012760A (es)
PE (1) PE20210368A1 (es)
PH (1) PH12020552152A1 (es)
SG (1) SG11202009103WA (es)
WO (1) WO2020002320A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112199A1 (es) 2017-06-20 2019-10-02 Hoffmann La Roche Derivados de piridina como agonistas inversos del receptor cannabinoide 2
CN112074513A (zh) 2018-06-27 2020-12-11 豪夫迈·罗氏有限公司 作为优先大麻素2激动剂的吡啶和吡嗪衍生物
CA3235177A1 (en) 2021-10-28 2023-05-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
ATE407119T1 (de) * 2004-02-24 2008-09-15 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
KR20070116066A (ko) 2005-03-31 2007-12-06 쉐링 코포레이션 스피로사이클릭 트롬빈 수용체 길항제
FR2887550A1 (fr) 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
DE602007006531D1 (de) * 2006-10-04 2010-06-24 Hoffmann La Roche Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
EP2311443A1 (en) 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
LT2928882T (lt) * 2012-12-07 2017-03-27 F. Hoffmann-La Roche Ag Pirazino dariniai kaip cb2 receptoriaus agonistai
US9303012B2 (en) * 2012-12-07 2016-04-05 Hoffman-La Roche Inc. Pyridine-2-amides useful as CB2 agonists
MX2016012689A (es) * 2014-04-04 2016-12-14 Hoffmann La Roche Piridin-2-amidas utiles como agonistas del receptor 2 cannabinoide (cb2).
CA2944256A1 (en) * 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists

Also Published As

Publication number Publication date
IL279725B1 (en) 2023-12-01
IL279725A (en) 2021-03-01
SG11202009103WA (en) 2020-10-29
US20210115011A1 (en) 2021-04-22
CO2020011855A2 (es) 2020-10-20
CL2020003331A1 (es) 2021-05-07
JP7445610B2 (ja) 2024-03-07
KR20210028202A (ko) 2021-03-11
CA3096777A1 (en) 2020-02-02
MX2020012760A (es) 2021-03-25
EP3814329A1 (en) 2021-05-05
AU2019294256A1 (en) 2020-09-24
IL279725B2 (en) 2024-04-01
JP2021529157A (ja) 2021-10-28
EP3814329B1 (en) 2024-01-17
MA53002A (fr) 2021-05-05
CN112262132A (zh) 2021-01-22
PH12020552152A1 (en) 2021-07-05
PE20210368A1 (es) 2021-02-26
WO2020002320A1 (en) 2020-01-02
BR112020025013A2 (pt) 2021-03-23
EP3814329C0 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
PH12020552152A1 (en) Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
EP4001273A3 (en) Aminopyrimidines as alk inhibitors
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
AU2018274723A1 (en) Benzimidazolone derived inhibitors of BCL6
CR20210265A (es) Derivados de aminopirimidina/pirazina como inhibidores de ctps1
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
MX2021003427A (es) Nuevos oxadiazoles.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
SG10201809066TA (en) 5,6-Disubstituted Pyridine-2-Carboxamides and 5,6-Disubstituted Pyrazine-2-Carboxamides as Cannabinoid Receptor Agonists
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists